FAS and ovarian carcinoma: According to our in vitro and in vivo data, we believe that FBA-TPQ can inhibit ovarian carcinoma growth by triggering the Fas-related/ROS-associated, and PI3K-Akt mediated/p53-MDM2-related increase in cellular apoptosis and cell cycle arrest and the decrease in cell proliferation (Fig. 5).